<DOC>
	<DOCNO>NCT01702090</DOCNO>
	<brief_summary>The purpose study provide early access TMC114 administer low-dose ritonavir ( TMC114/r ) antiretrovirals ( ARVs ) HIV-1-infected patient receive previous HIV treatment receive early treatment without TMC114 regimen .</brief_summary>
	<brief_title>Early Access Low-dose Ritonavir ( TMC114/r ) Other Antiretrovirals ( ARVs ) Treatment-naive Early Treatment Experienced HIV-1 Patients</brief_title>
	<detailed_description>This single-treatment-group , open-label ( patient study personnel know identity treatment give ) , single-center study . The primary goal study provide early access TMC114 administer low-dose ritonavir ( TMC114/r ) antiretrovirals ( ARVs , agent use treat viral infection ) . This study intend HIV-1-infected patient receive previous HIV treatment ( treatment-naive patient ) receive early treatment without TMC114 regimens ineligible participate sponsor HIV-1 study . This study monitor evaluate safety efficacy TMC114/r combination ARVs course study . Treatment TMC114/r continue virologic failure ( inability achieve maintain suppression viral replication ) , treatment-limiting toxicity , loss follow-up , study withdrawal , pregnancy , discontinuation TMC114 development TMC114 become reimbursable treatment-naive patient TMC114 become commercially available treatment-experienced patient .</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<criteria>Patients document HIV1 infection ineligible participation Sponsor 's HIV1 trial Patients never treat antiretroviral ( ARV ) medication prior early treatmentexperienced without TMC114 regimen , include limited treatment option due virological failure intolerance regimens Patient 's general medical condition , investigator 's opinion evaluate patient eligible TMC114 contain regimen , interfere assessment completion trial Any active clinically significant disease finding screen medical history physical examination either resolve stabilize least 30 day screen phase trial Evidence active liver disease , acute viral hepatitis , liver impairment/dysfunction cirrhosis irrespective liver enzyme level ; however , patient coinfected hepatitis B C include condition judge clinically stable Grade 3 4 laboratory abnormality define Division AIDS ( DAIDS ) . Calculated creatinine clearance ( CrCl ) less 50 ml/min Female patient pregnant breastfeeding , childbearing potential without use effective nonhormonal birth control method willing continue practice birth control method screen last 30 day end treatment period Any condition ( include limit alcohol and/or drug abuse ) , opinion investigator , could compromise patient 's safety compliance study protocol procedure</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>TMC114</keyword>
	<keyword>Darunavir</keyword>
	<keyword>PREZISTA</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>Antiretrovirals</keyword>
	<keyword>Early access</keyword>
	<keyword>Early treatment</keyword>
	<keyword>Treatment naive</keyword>
</DOC>